Azactam and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Azactam (aztreonam), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Cubicin, and have Depression.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Azactam. It is created by eHealthMe based on reports of 1,039 people who have side effects when taking Azactam from the FDA, and is updated regularly.

What is Azactam?

Azactam has active ingredients of aztreonam. eHealthMe is studying from 1,044 Azactam users. Check the latest studies of Azactam.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 08, 2026

1,039 people reported to have side effects when taking Azactam.
Among them, 24 people (2.31%) have Interstitial lung disease.

Could Azactam cause Interstitial lung disease?

Among these 24 people:

How long have people been on Azactam when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Azactam? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Interstitial lung disease when taking Azactam? *

What are other drugs people take besides Azactam? *

What are other side effects people have besides Interstitial lung disease? *

Renal Impairment (severely reduced kidney function): 4 people, 16.67%
Blood Urea Increased: 3 people, 12.50%
Aspartate Aminotransferase Increased: 3 people, 12.50%
Graft Versus Host Disease In Lung (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the lung): 2 people, 8.33%
Pneumonia: 2 people, 8.33%
Diarrhea: 2 people, 8.33%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 8.33%
Urinary Tract Infection: 2 people, 8.33%
Cryptogenic Organising Pneumonia (small airways (bronchioles) and air exchange sac (alveoli) become inflamed with connective tissue): 2 people, 8.33%
Haemoglobin Decreased: 2 people, 8.33%

What are the existing conditions these people have? *

Staphylococcal Infection (an infection with staphylococcus bacteria): 11 people, 45.83%
High Blood Pressure: 11 people, 45.83%
Dyslipidaemia (abnormal amount of lipids): 11 people, 45.83%
Depression: 11 people, 45.83%
Urinary Tract Infection: 3 people, 12.50%
Lung Adenocarcinoma Stage Iii (the cancer has spread to nearby tissue or too far away lymph nodes): 2 people, 8.33%
Immunodeficiency Disorders: 2 people, 8.33%
Endocarditis (inflammation in heart muscle): 2 people, 8.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 8.33%
Arthritis Infective (purulent invasion of a joint by an infectious agent which produces arthritis): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Azactam and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Azactam:

Azactam (1,044 reports)

Browse all side effects of Azactam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,500 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on aztreonam (the active ingredients of Azactam) and Azactam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.